I have had migraine (with vertigo, but they don’t always happen at same time) for over 15 yrs, and been recently diagnosed with Meniere’s.

My neurologist prescribed Ajovy injection for me about a year ago, I stopped taking it after a few months because the price skyrocketed from $5 to over $700. That’s when all the stuff about what’s in the vaxx started coming out. About a month ago I went back for my follow appointment and told him about the price change. So he was able to prescribe it for me for $5 again at the pharmacy. It’s a once a month injection. But now because of what’s in the vaxx, I’m worried about the contents of this medicine, so still have not taken it.

Does anyone have any thoughts about this medicine?

Here is the some info on Ajovy ... Fremanezumab-VFRM ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422958/

~~Some info from this site ...

Fremanezumab-vfrm (hereafter referred to as fremanezumab) [AJOVY™] is a fully humanized monoclonal antibody (IgG2Δa) developed by Teva Pharmaceuticals to selectively target calcitonin gene-related peptide (a vasodilatory neuropeptide involved in the pathophysiology of migraine). Its use has been associated with significant reductions in migraine frequency, the requirement for acute headache medication use and headache-related disability compared with placebo in multinational, phase III studies, and in September 2018 fremanezumab was approved by the US FDA for the preventive treatment of migraine in adults. A regulatory assessment for fremanezumab as a preventive treatment of migraine in adults is underway in the EU. Fremanezumab is also undergoing phase III development for the preventive treatment of cluster headache (although a phase III chronic cluster headache study has been suspended due to the results of a prespecified futility analysis) and phase II development for the preventive treatment of post-traumatic headache disorder. This article summarizes the milestones in the development of fremanezumab leading to this first approval in the USA for the preventive treatment of migraine in adults.

~~It looks like it originally came from Pfizer ...

In January 2013, Labrys Biologics acquired the worldwide rights to fremanezumab from Pfizer [8]. Under the terms of the agreement, Pfizer will be eligible to receive milestone payments and sales royalties [8]. In July 2014, Teva Pharmaceutical Industries (hereafter referred to as Teva) acquired Labrys Biologics (and the fremanezumab programme) for an upfront payment of US$200 million and contingent payments of up to US$625 million (subject to the achievement of certain development milestones) [9, 10]. In May 2017, Teva and Otsuka Pharmaceuticals (hereafter referred to as Otsuka) entered into a development and commercialization agreement [11]. Under the terms of this agreement, Otsuka acquires exclusive rights to fremanezumab and will fund clinical studies in Japan, while Teva receives a payment of US$50 million and will be eligible for milestone payments upon filing and regulatory approval in Japan and upon the achievement of revenue targets [11].

Teva is the company that has Ajovy now ...

https://www.tevapharm.com/search-results/?keywords=Fremanezumab